Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHT103
- Development stage
- Unknown
- Lead developer
- Nanjing Miracle Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CHT103 (also known as CHT-103) is an allogeneic, dual-target universal chimeric antigen receptor T-cell (CAR-T) therapy currently in preclinical development by Nanjing Miracle Biotechnology. Designed as an off-the-shelf cell therapy, CHT103 aims to overcome the logistical and manufacturing challenges associated with patient-specific autologous CAR-T therapies. While the candidate is positioned within Nanjing Miracle Biotechnology's pipeline for potential applications in oncology or autoimmune diseases, the specific molecular targets and therapeutic indications for CHT103 have not been publicly disclosed.
- Other names
- CHT 103CHT103CHT-103dual-target universal CAR-T
Beyond the preview
Go deeper on CHT103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHT103.